

# 4DMedical commences scanning in US at Providence St. Joseph

6 April 2022

## Highlights

- 4DMedical kicks off clinical pilot with first scans at Providence St. Joseph Hospital in Orange, California
- Providence St. Joseph is one of 52 hospitals in the world-class Providence health care network
- 4DMedical's XV LVAS™ software is being used to assist in screening for multiple respiratory conditions, including Chronic Obstructive Pulmonary Disease (COPD) and long-COVID
- Clinical pilots form an important part of 4DMedical's commercialisation strategy, allowing institutions to implement and trial the Company's end-to-end solution ahead of potential commercial integration

---

Melbourne, Australia, 6 April 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") today announces the commencement of an important US-based clinical pilot, with first scans occurring at Providence St. Joseph Hospital in Orange, California. This pilot represents the first commercial usage of XV LVAS™ in the United States (US), with multiple scans across a range of conditions including COPD and long-COVID already completed.

## 4DMedical progresses its first clinical pilot in the key US market

This pilot is being conducted at Providence St. Joseph Hospital in Orange County, California. St. Joseph Hospital is one of 52 hospitals within the Providence Health & Services network, the third largest not-for-profit health system in the US.

These successful scans at St. Joseph Hospital build on previous and concurrent use of XV Technology™ in clinical trials undertaken at other US sites including Johns Hopkins Medical Center, Cleveland Clinic, Vanderbilt University Medical Center, Duke University Hospital and the University of Miami.

## This US pilot is a key milestone in plans to grow 4DMedical's global footprint

4DMedical has already taken important steps towards entering the Australian market. The Company now offers its unique four-dimensional respiratory scans on a commercial basis through the I-MED Radiology Network ("I-MED"), the largest provider of medical imaging in Australia. I-MED adopted 4DMedical's XV Technology™ following the successful completion of a clinical pilot program. 4DMedical is deploying a similar process in the US with the start of the clinical pilot program at Providence St. Joseph Hospital located in California.

## Providence St. Joseph Hospital Chief Executive Dr Jeremy Zoch PhD said:

*"The potential for 4DMedical's XV Technology to play a role in the surveillance of lung function is unprecedented, along with the capacity to monitor the effectiveness of pharmaceutical and other interventions for the treatment of those diseases. Doctors have never been able to see lungs with this level*



*of richness and detail before. We're proud of our commitment to bring the latest in life-changing technology to doctors, patients and community."*

**4DMedical Founder, Chief Executive Officer and Chief Technology Officer Dr Andreas Fouras PhD said:**

"We are delighted to commence commercial imaging in the United States. This pilot will help open the door to the huge US diagnostics market and take us closer to realising the commercial potential of our innovative technology. This progress comes hot on the heels of our recent unveiling of an operational XV Scanner incorporating the Company's proprietary XV Technology.

While the US pilot has been slower to get moving than we anticipated, we are excited by the momentum it injects into our commercialisation efforts at this time. Its realisation reflects well on the commitment of the whole 4DMedical team to see its way through recent multiple challenges, the COVID-19 pandemic included. As the pilot progresses, we expect it will clearly demonstrate that our technology markedly improves doctors' ability to diagnose and treat a range of respiratory diseases."

**-ENDS-**

Authorised by the 4DMedical Board of Directors.

## **Contacts**

### **Corporate**

Melanie Leydin  
Company Secretary  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

### **Media**

Julia Maguire  
+ 61 419 815 386  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

## **About 4DMedical**

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical Limited was founded in 2012 and is listed on the Australian Securities Exchange (ASX:4DX).

4DMedical is a medical technology company focused on delivering the global gold standard in respiratory diagnostics for all lung disorders, including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique and transformative XV Technology™ accurately and quickly scans lung function as the patient breathes, enabling early diagnosis and the monitoring of changes over time.

Our Software-as-a-Service (SaaS) delivered Ventilation Reports provide information and insights far beyond the capabilities of conventional modalities, showing subtle variations in lung function down to the finest details in specific regions of each lung, and with lower exposure to radiation than traditional methods.

Respiratory diagnostics is a US\$31 billion per annum global industry. 4DMedical is disrupting this sector and is committed to providing better information to doctors and patients about lung function.

*Better information means better decisions and better outcomes.*

Learn more: <https://4dmedical.com>